Phase 3Not yet recruitingHealthspan endpoint
Fighting Osteoporosis With Risedronate Co-Therapy During Incretin (FORTIFY)
Bisphosphonate Co-Therapy to Preserve Musculoskeletal Health in Older Adults Using Tirzepatide
- Sponsor
- Wake Forest University Health Sciences (Academic or other)
- Enrollment
- 96 planned
- Conditions
- Obesity
- Interventions
- Tirzepatide; Risedronate; Placebo
- Ages
- adults, older adults
- Registry
- NCT07943754
Full record on ClinicalTrials.gov
From the registry
Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.
Primary outcomes
- Change in Hip Bone Mineral Density
History
Primary completion expected
Expected to start
Registered
In the news
ResearchMedical Xpress (opens Medical Xpress in a new tab)
Resistance training cuts lean mass loss 25% during tirzepatide obesity treatment
In a 40-week randomized trial of 120 adults aged 50–70, three weekly sessions increased strength 10%, versus a 10% decline with tirzepatide alone, researchers report.
Also in Nature Medicine (opens Nature Medicine in a new tab)
